key: cord-1055752-txmhdad0
authors: Horby, P. W.; Emberson, J. R.; Mafham, M.; Campbell, M.; Peto, L.; Pessoa-Amorim, G.; Spata, E.; Staplin, N.; Lowe, C.; Chadwick, D. R.; Brightling, C.; Stewart, R.; Collini, P.; Ashish, A.; Green, C. A.; Prudon, B.; Felton, T.; Kerry, A.; Baillie, J. K.; Buch, M. H.; Day, J. N.; Faust, S. N.; Jaki, T.; Jeffery, K.; Juszczak, E.; Knight, M.; Lim, W. S.; Montgomery, A.; Mumford, A.; Rowan, K.; Thwaites, G.; Haynes, R.; Landray, M. J.
title: Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
date: 2022-03-03
journal: nan
DOI: 10.1101/2022.03.02.22271623
sha: 86a40a81e591877f177fd4cb1ff70ae6d8acb370
doc_id: 1055752
cord_uid: txmhdad0

Background: We evaluated the use of baricitinib, a Janus kinase (JAK) 1/2 inhibitor, for the treatment of patients admitted to hospital because of COVID-19. Methods: This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised for COVID-19. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group). The primary outcome was 28-day mortality assessed in the intention-to-treat population. A meta-analysis was conducted that included the results from the RECOVERY trial and all previous randomised controlled trials of baricitinib or other JAK inhibitor in patients hospitalised with COVID-19. Findings: Between 2 February 2021 and 29 December 2021, 8156 patients were randomly allocated to receive usual care plus baricitinib versus usual care alone. At randomisation, 95% of patients were receiving corticosteroids and 23% receiving tocilizumab (with planned use within the next 24 hours recorded for a further 9%). Overall, 513 (12%) of 4148 patients allocated to baricitinib versus 546 (14%) of 4008 patients allocated to usual care died within 28 days (age-adjusted rate ratio 0.87; 95% CI 0.77-0.98; p=0.026). This 13% proportional reduction in mortality was somewhat smaller than that seen in a meta-analysis of 8 previous trials of a JAK inhibitor (involving 3732 patients and 425 deaths) in which allocation to a JAK inhibitor was associated with a 43% proportional reduction in mortality (rate ratio 0.57; 95% CI 0.45-0.72). Including the results from RECOVERY into an updated meta-analysis of all 9 completed trials (involving 11,888 randomised patients and 1484 deaths) allocation to baricitinib or other JAK inhibitor was associated with a 20% proportional reduction in mortality (rate ratio 0.80; 95% CI 0.71-0.89; p<0.001). In RECOVERY, there was no significant excess in death or infection due to non-COVID-19 causes and no excess of thrombosis, or other safety outcomes. Interpretation: In patients hospitalised for COVID-19, baricitinib significantly reduced the risk of death but the size of benefit was somewhat smaller than that suggested by previous trials. The total randomised evidence to date suggests that JAK inhibitors (chiefly baricitinib) reduce mortality in patients hospitalised for COVID-19 by about one-fifth.

In patients admitted to hospital with severe COVID-19, the host immune response is 61 thought to play a key role in driving an acute inflammatory process resulting in hypoxic 62 respiratory failure that may require mechanical ventilator support or lead to death. 1,2 It 63 has previously been shown that the use of dexamethasone and other corticosteroids 64 reduces the risk of death in patients with severe hypoxic and that the addition 65 of an interleukin-6 (IL-6) receptor blocker further reduces the risk of death in these 66

Baricitinib is an inhibitor of Janus kinase (JAK)1 and JAK2 that is licensed in the UK for 68 the treatment of rheumatoid arthritis and atopic dermatitis. The JAKs are a family of four 69 transmembrane protein kinases (JAK1, JAK2, JAK3 and TYK2) that mediate intracellular 70 signalling of a range of extracellular cytokines and interferons. 7 JAK inhibition prevents 71 downstream phosphorylation and hence activation of signal transducers and activators of 72 transcription (STAT). Since the JAK-STAT pathway mediates the effect of several 73 cytokines, including IL-6, that are raised in severe COVID-19, JAK inhibitors have been 74

proposed as a potential therapeutic option for severe 9 Baricitinib also has 75 moderate inhibitory activity against tyrosine kinase 2 (TYK2) and genetic data support a 76 causal link between high TYK2 expression and life-threatening COVID-19. 10 Baricitinib 77 was also predicted, using artificial intelligence, to reduce endocytosis of SARs-CoV-2 into 78 lung cells by inhibiting AP2-associated protein kinase 1 (AAK1) and cyclin G associated 79 kinase (GAK). 8 80 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Baricitinib was tested in combination with remdesivir in the Adaptive Covid-19 Treatment 81

Trial-2 (ACTT-2) and was shown to improve time to recovery compared to remdesivir 82 alone (rate ratio for recovery 1.16, 95% CI 1.01-1.32). There was also a suggestion that 83 28-day mortality may be reduced by baricitinib (HR 0.65, 95% CI 0.39-1.09). 11 As a 84 consequence, the US Food and Drug Administration (US FDA) issued an emergency use 85 authorisation for the use of baricitinib in combination with remdesivir, for the treatment of 86 COVID-19 in hospitalised patients requiring oxygen, invasive mechanical ventilation or 87 extracorporeal membrane oxygenation (ECMO). 12 Since then, a further 7 randomised 88 trials of JAK inhibitors have reported, [13] [14] [15] [16] [17] [18] [19] of which two have reported a significant 89 reduction in mortality. 16, 19 Here we report the results of a large randomised controlled trial 90 of baricitinib in patients hospitalised with severe COVID-19. 91

The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigator-95 initiated, individually randomised, controlled, open-label, platform trial to evaluate the 96 effects of potential treatments in patients hospitalised with COVID-19. Details of the trial 97 design and results for other possible treatments (dexamethasone, hydroxychloroquine, 98 lopinavir-ritonavir, azithromycin, tocilizumab, convalescent plasma, colchicine, aspirin, 99 and casirivimab plus imdevimab) have been published previously. 3, 5, [20] [21] [22] [23] [24] [25] [26] The trial is 100 underway at 177 hospital organisations in the United Kingdom supported by the National 101

Institute for Health Research Clinical Research Network (appendix pp 3-27). Of these, 102

Eligible and consenting patients were assigned in a 1:1 ratio to either usual standard of 124 care plus baricitinib or usual standard of care alone, using web-based simple (unstratified) 125 randomisation with allocation concealed until after randomisation (appendix pp 29-33) . 126

For some patients, baricitinib was unavailable at the hospital at the time of enrolment or 127 was considered by the managing physician to be either definitely indicated or definitely 128 contraindicated. These patients were excluded from the randomised comparison between 129 baricitinib versus usual care. Patients allocated to baricitinib were to receive baricitinib 4 130 mg daily for 10 days (or until discharge if sooner). The dose was to be reduced for patients 131 with eGFR <60 mL/min/1.73m 2 or receiving probenecid, and for children aged <9 years 132 (see appendix p 28 for dosing details). Prior or subsequent administration of tocilizumab 133 was permitted at the discretion of the managing doctor who was also responsible for 134 considering the risk of infection and gastrointestinal perforation (particularly in the context 135 of corticosteroid use). 136

As a platform trial, and in a factorial design, patients could be simultaneously randomised 137 to other treatment groups: i) colchicine versus usual care, ii) aspirin versus usual care, iii) 138 dimethyl fumarate versus usual care, iv) casirivimab+imdevimab versus usual care, and investigators, and all other individuals involved in the trial were masked to outcome data 143 during the trial. 144 145 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Procedures 146

An online follow-up form was completed by site staff when patients were discharged, had 147 died, or at 28 days after randomisation, whichever occurred first (appendix pp 39-46). 148

Information was recorded on adherence to allocated trial treatment, receipt of other 149 COVID-19 treatments, duration of admission, receipt of respiratory or renal support, new 150 cardiac arrhythmia, thrombosis, clinically significant bleeding, non-COVID infection, and 151 vital status (including cause of death). In addition, routinely collected healthcare and 152 registry data were obtained, including information on vital status at day 28 (with date and 153 cause of death); discharge from hospital; and receipt of respiratory support or renal 154 replacement therapy. 155

Outcomes were assessed at 28 days after randomisation, with further analyses specified 157 at 6 months. The primary outcome was 28-day all-cause mortality. Secondary outcomes 158 were time to discharge from hospital, and, among patients not on invasive mechanical 159 ventilation at randomisation, the composite outcome of invasive mechanical ventilation 160 (including extra-corporeal membrane oxygenation) or death. Prespecified subsidiary 161 clinical outcomes were use of invasive or non-invasive ventilation among patients not on 162 any ventilation at randomisation, time to successful cessation of invasive mechanical 163 ventilation (defined as cessation of invasive mechanical ventilation within, and survival to, 164 28 days), and use of renal dialysis or haemofiltration. Prespecified safety outcomes were 165 cause-specific mortality, major cardiac arrhythmia, thrombotic and major bleeding events, 166 and other infections. Information on suspected serious adverse reactions was collected 167 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 in an expedited fashion to comply with regulatory requirements. Details of the methods 168 used to ascertain and derive outcomes are provided in the appendix (pp.141-161) . 169 170

For all outcomes, intention-to-treat analyses compared patients randomised to baricitinib 172 with patients randomised to usual care. Through the play of chance in the unstratified 173 randomisation, patients in the baricitinib group were slightly older than patients in the 174 usual care group (Table 1 ). In accordance with the prespecified statistical analysis plan 175 for dealing with baseline imbalances in important prognostic factors (appendix p 125), 176

estimates of the effect of allocation to baricitinib on major outcomes were adjusted for 177 age in three groups (<70 years, ≥70 to <80 years, and ≥80 years). (Exploratory analyses 178 were conducted without this adjustment and, separately, with further adjustment for other 179 predefined subgroups of interest.) 180

For the primary outcome of 28-day mortality, the hazard ratio from an age-adjusted Cox 181 model was used to estimate the mortality rate ratio. We constructed Kaplan-Meier survival 182 curves to display cumulative mortality over the 28-day period. We used the same method 183 to analyse time to hospital discharge and successful cessation of invasive mechanical 184 ventilation, with patients who died in hospital right-censored on day 29. Median time to 185 discharge was derived from Kaplan-Meier estimates. For the pre-specified composite 186 secondary outcome of progression to invasive mechanical ventilation or death within 28 187 days (among those not receiving invasive mechanical ventilation at randomisation), and 188 the subsidiary clinical outcomes of receipt of ventilation and use of haemodialysis or 189 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 haemofiltration, the precise dates were not available and so a log-binomial regression 190 model was used to estimate the age-adjusted risk ratio. Estimates of rate and risk ratios 191 (both denoted RR) are shown with 95% confidence intervals. 192

Prespecified analyses of the primary outcome were done in subgroups defined by six 193 characteristics at the time of randomisation (age, sex, ethnicity, days since symptom 194 onset, level of respiratory support, and use of corticosteroids) with tests of heterogeneity 195 or trend, as appropriate. The full database is held by the study team which collected the 196 data from study sites and performed the analyses at the Nuffield Department of 197

Population Health, University of Oxford (Oxford, UK). 198

The independent Data Monitoring Committee reviewed unblinded analyses of the study 199 data and any other information considered relevant to the trial at intervals of around 2 to 200 4 weeks (depending on speed of enrolment) and was charged with determining if, in their 201 view, the randomised comparisons in the study provided evidence on mortality that was 202 strong enough (with a range of uncertainty around the results that was narrow enough) 203 to affect national and global treatment strategies (see appendix p 50). 204

As stated in the protocol, appropriate sample sizes could not be estimated when the trial 205 was being planned. On the advice of the Trial Steering Committee, recruitment to this 206 comparison was closed on 29 December 2021 when over 8150 patients had been 207 randomised and the blinded 28-day mortality rate was 12.9% (suggesting there would be 208 at least 1050 deaths), giving at least 90% power to detect a proportional risk reduction in 209 the primary outcome of one-fifth at 2P=0.01. The Trial Steering Committee and all other 210 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 individuals involved in the trial were masked to outcome data until after the close of 211

For the primary outcome of 28-day mortality, the results from the RECOVERY trial were 213 subsequently included in a meta-analysis of results from all previous randomised 214 controlled trials of a JAK inhibitor for patients hospitalised with COVID-19. Details of the 215 systematic search methods are provided in the appendix (p 28). For each trial, we 216 compared the observed number of deaths among patients allocated to the JAK inhibitor 217 with the expected number if all patients were at equal risk (i.e., we calculated the observed 218 minus expected statistic [o-e], and its variance v). For RECOVERY, these were estimated 219 from the age-adjusted mortality log rate ratio and its standard error but for other trials, 220

where the exact timing of each death was not available, these were calculated from 221 standard formulae for 2 × 2 contingency tables. We then combined trial results using the 222 log of the mortality rate ratio calculated as the inverse-variance-weighted average S/V 223 with variance 1/V (and hence with 95% CI S/V ±1·96/√V), where S is the sum over all 224 trials of (o-e) and V is the sum over all trials of v. 27 Such meta-analyses do not make any 225 assumptions about the nature of any true heterogeneity in the log RR between different 226 trials (in particular it does not assume that it is zero). Analyses were performed using SAS 227 version 9.4 and R version 4.0.3. The trial is registered with ISRCTN (50189673) and 228 clinicaltrials.gov (NCT04381936). 229

The funders of the study had no role in study design, data collection, data analysis, data 231 interpretation, or writing of the report. Baricitinib was provided from standard National 232 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101/2022.03.02.22271623 doi: medRxiv preprint Health Service (NHS) stocks. The corresponding authors had full access to all the data 233 in the study and had final responsibility for the decision to submit for publication. 234

Between 2 February 2021 and 29 December 2021, 8156 (75%) of 10852 patients enrolled 237 into the RECOVERY trial at one of the 169 participating sites were eligible to be randomly 238 allocated to baricitinib (i.e. the treatment was available in the hospital at the time and the 239 attending clinician was of the opinion that the patient had no known indication for or 240 contraindication to it, figure 1). 4148 patients were randomly allocated to baricitinib and 241 4008 were randomly allocated to usual care. The mean age of study participants in this 242 comparison was 58.1 years (SD 15.5) with a chance imbalance whereby patients 243 randomly allocated to baricitinib were, on average, 0.8 years older than those allocated 244 usual care group (Table 1) . At randomisation, 7771 (95%) patients were receiving 245 corticosteroids, 1872 (23%) were receiving tocilizumab (with planned use within the next 246 24 hours recorded for a further 756 [9%]) ( Table 1 , Webtable 1). About two-thirds were 247 receiving simple oxygen and one quarter were receiving non-invasive ventilation, with 248 small numbers receiving invasive mechanical ventilation or no respiratory support at all. 249 3420 (42%) patients had received at least one dose of a SARS-CoV-2 vaccine. 250

The follow-up form was completed for 4084 (98%) patients in the baricitinib group and 251 3950 (99%) patients in the usual care group. Among patients with a completed follow-up 252 form, 91% allocated to baricitinib were reported to have received the treatment compared 253 with <1% allocated to usual care (figure 1, webtable 2). Use of other treatments for 254 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101/2022.03.02.22271623 doi: medRxiv preprint COVID-19 was broadly similar among patients allocated baricitinib and among those 255 allocated usual care, with nine-tenths receiving a corticosteroid, one-fifth receiving 256 remdesivir, and one-tenth receiving casirivimab+imdevimab, although use of tocilizumab 257 during the follow-up period was slightly lower in the baricitinib group than in the usual care 258 group (26% vs. 29%) (webtable 2). 259

Primary and secondary outcome data are known for >99% of randomly assigned patients. 260

Allocation to baricitinib was associated with a significant reduction in the primary outcome 261 of 28-day mortality compared with usual care alone: 513 (12%) of 4148 patients in the 262 baricitinib group died vs 546 (14%) of 4008 patients in the usual care group (age-adjusted 263 rate ratio 0·87; 95% CI 0·77-0·98; p=0·026; table 2, figure 2). Similar proportional risk 264 reductions were seen in sensitivity analyses adjusted for all pre-specified subgroups (as 265 listed in figure 3 ) and without adjustment for the 0.8 year age-imbalance between 266 randomised groups (webtable 3), and when restricted to participants with a positive 267 SARS-CoV-2 PCR test (age adjusted RR 0.90, 95% CI 0.79-1.02). 268

The proportional effect of baricitinib on mortality was consistent across all pre-specified 269 subgroups (Figure 3) , including by level of respiratory support received (test for trend 270 p=0.33), use of dexamethasone at randomisation (test for heterogeneity p=0.41) and, in 271 exploratory analyses, by baseline CRP level (test for trend p=0.93) or by use of 272 tocilizumab or remdesivir at baseline (tests for heterogeneity p=0.53 and p=0.12, 273 respectively) (webfigure 1). There was no evidence that the effect of baricitinib on 274 mortality varied depending on concurrent randomised allocation to colchicine, aspirin or 275 casirivimab+imdevimab (all interaction p-values >0.32). 276 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 3, 2022. Among patients not on invasive mechanical ventilation at baseline, allocation to baricitinib 280 was associated with a lower risk of progressing to the composite secondary outcome of 281 invasive mechanical ventilation or death (16% vs. 17%, age-adjusted risk ratio 0·90, 95% 282 CI 0·81 to 0·99) (table 2 and webfigure 3). The proportional effects of baricitinib versus 283 usual care on these secondary outcomes were also similar across all pre-specified 284

There were no significant differences in the pre-specified subsidiary clinical outcomes of 286 cause-specific mortality other than that due to COVID-19 (Webtable 4) or in use of 287 ventilation, successful cessation of invasive mechanical ventilation, or receipt of 288 haemodialysis or haemofiltration (table 2) . There were no significant differences in the 289 rates of non-coronavirus infection, thrombotic events, or clinically significant bleeding, but 290 allocation to baricitinib was associated with a nominally significant reduction in new onset 291 cardiac arrythmia (2.3% vs 3.1%, p=0.017) (webtable 5). There were 13 reports of a 292 serious adverse reaction believed to be related to treatment with baricitinib (webtable 6), 293

including 5 participants with a serious non-COVID infection, 3 with a bowel perforation 294 and 2 with a pulmonary embolism. 295

Our systematic search identified 8 previous trials of a JAK inhibitor for the treatment of 296 patients hospitalised with COVID-19, involving a total of 3732 randomised patients and 297 425 deaths (figure 4 and webtable 8). 11, [13] [14] [15] [16] [17] [18] [19] In these 8 trials, allocation to a JAK inhibitor 298 was associated with a significant 43% proportional reduction in mortality (rate ratio 0.57; 299 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101/2022.03.02.22271623 doi: medRxiv preprint 95% CI 0.45-0.72). This was significantly greater than the mortality risk reduction seen in 300 RECOVERY (test for heterogeneity, p=0.001). After inclusion of the results from 301 RECOVERY into this meta-analysis, the average mortality rate ratio from all 9 trials, now 302 involving 11,888 randomised patients and 1484 deaths, was 0.80 (0.71-0.89; p<0.001). 303

In this large, randomised trial, allocation to baricitinib significantly reduced 28-day 306 mortality by about one-eighth. This is somewhat less than had been suggested by eight 307 previous randomised, controlled trials of a JAK inhibitor which, together, suggested that 308 allocation to a JAK inhibitor in COVID-19 patients reduces 28-day mortality by about two-309 fifths. RECOVERY was more than three times the size (in terms of statistical information) 310 of these 8 previous trials put together. When combined in an updated meta-analysis, 311 allocation to baricitinib or another JAK inhibitor in these 9 trials was associated with a 312 significant reduction in 28-day mortality of one-fifth. Although not as large as perhaps 313 previously thought, this still represents an important reduction in mortality risk for patients 314 hospitalised because of Strengths of the RECOVERY trial included that it was randomised, had a large sample 316 size, broad eligibility criteria and more than 99% of patients were followed up for the 317 primary outcome. The study has some limitations: this randomised trial is open label (i.e., 318 participants and local hospital staff are aware of the assigned treatment), however, the 319 outcomes are unambiguous and were ascertained without bias through linkage to routine 320 health records. Use of tocilizumab during the follow-up period was slightly lower among 321 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) immunomodulatory treatments known to reduce mortality in this setting was similar in 325 those allocated baricitinib and those allocated usual care. Information on radiological, 326 virological or physiological outcomes was not collected. 327

The smaller effect size observed in RECOVERY compared to earlier trials of baricitinib 328 may simply be a chance effect. However, several other factors could have contributed. 329

The patient population in RECOVERY may have been broader than some of the other 330 trials, which may have been enriched for patients more likely to benefit from 331 immunomodulatory therapy. The use of concomitant therapies has varied between the 332 trials. For example, the ACTT-2 trial did not permit the use of dexamethasone as a 333 treatment for COVID-19, and ACTT-2, COV-BARRIER, RUXCOVID and the study by 334

Guimaraes and colleagues all excluded the use of an IL-6 receptor blocker. 11, 15, 16, 18 Other 335 factors that may be different between the trials include the prevalence of SARS-CoV-2 336 vaccination and the predominant circulating SARS-CoV-2 variant. However, there is no 337 reason to believe that, among patients admitted to hospital with severe COVID-19 338 requiring oxygen or ventilatory support, the proportional risk reduction in mortality with 339 baricitinib, a host-directed therapy, would differ by vaccination status or SARS-CoV-2 340 variant. Despite the heterogeneity of effect between RECOVERY and the previous 8 trials 341

combined, the overall result of the meta-analysis (which makes no assumptions about the 342 nature of any true differences in treatment effects between the different populations 343 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. corticosteroids, in patients with severe or critical COVID-19. 29 The results from the 363 RECOVERY trial and our meta-analysis, considerably strengthen the evidence that 364 baricitinib can reduce mortality and other adverse clinical outcomes in patients 365 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101/2022.03.02.22271623 doi: medRxiv preprint hospitalised with COVID-19 and support the co-administration of baricitinib with 366 dexamethasone and/or an IL-6 receptor blocker. 367

In summary, this large, randomised trial confirms evidence from previous smaller trials 368 that treatment with baricitinib can reduce mortality in patients hospitalised with COVID-369 19, although the size of the benefit is about half that previously thought. The benefits 370 appear to be consistent regardless of treatment with remdesivir, systemic corticosteroids 371 and/or an IL-6 receptor blocker such as tocilizumab. The results support the use of 372 baricitinib in addition to other immunosuppressive therapies in patients hospitalised with 373 COVID-19. 374 375 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101/2022.03.02.22271623 doi: medRxiv preprint

We searched Medline, Embase, MedRxiv, bioRxiv and the WHO International Clinical 378 Trials Registry Platform from Sept 1, 2019 to Feb 13, 2022, for randomised controlled 379 trials evaluating the effect of bariticinib or another Janus Kinase (JAK) inhibitor in 380 patients hospitalised with COVID-19 using the search terms ("SARS-CoV-2.mp" OR 381 "SARS-CoV2" OR "SARSCoV2.mp" OR "COVID.mp" OR "COVID-19.mp" OR 382 "COVID19.mp" OR "2019-nCoV.mp" OR "Coronavirus.mp" or "Coronavirinae/") AND 383

("JAK inhibitor.mp or Janus kinase inhibitor/" OR "Janus kinase inhibitor.mp" OR 384 "Baricitinib.mp or baricitinib/" OR terms for other specific JAK inhibitors (listed in 385 appendix p 28) and using validated filters to select for randomised controlled trials. No 386 language restrictions were applied. 387

We identified eight relevant randomised trials with results available that assessed JAK 388 inhibitors in hospitalised patients with COVID-19: three assessed baricitinib, three 389 assessed ruxolitinib and two assessed tofacitinib. Six of the trials had been fully 390 published of which four were considered to be low risk of bias for the 28-day mortality 391 outcome with two having some concerns (one because of lack of information about pre-392 specified analyses and some imbalances between randomised groups of other 393 interventions given during the trial; the other because of lack of information about the 394 randomisation process, inconsistency in reporting of outcome endpoint timing and lack 395 of information about pre-specified analyses). A meta-analysis of these eight trials, which 396 included a total of 425 deaths among 3732 patients, suggested that allocation to a JAK 397 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 inhibitor was associated with a 43% proportional reduction in 28-day mortality (OR 0.57 398 [95% confidence interval 0.45-0.72]). 399

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is the largest 401 randomised trial of the effect of a JAK inhibitor in patients hospitalised with We found that in 8156 patients admitted to hospital with COVID-19, baricitinib reduced 403 28-day mortality by 13%, increased the probability of discharge alive within 28 days, 404 and, amongst patients who were not receiving invasive mechanical ventilation at 405 randomisation, reduced the probability of progression to the composite outcome of 406 invasive mechanical ventilation or death. The benefits were consistent in all subgroups 407 of patients, including those receiving a systemic corticosteroid and/or an IL-6 receptor 408

The randomised evidence from all 9 completed JAK inhibitor trials to date suggest that 411 treatment with baricitinib or an alternative JAK inhibitor reduces mortality by about one-412 fifth in hospitalised COVID-19 patients, including those already receiving a systemic 413 corticosteroid and/or an IL-6 receptor blocker. 414 415 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

The authors have no conflict of interest or financial relationships relevant to the submitted 443 work to disclose. No form of payment was given to anyone to produce the manuscript. All study materials are available online at www.recoverytrial.net. As described in the protocol, 453 the Trial Steering Committee will facilitate the use of the study data and approval will not 454 be unreasonably withheld. Deidentified participant data will be made available to bona 455 fide researchers registered with an appropriate institution within 3 months of publication. 456

However, the Steering Committee will need to be satisfied that any proposed publication 457

is of high quality, honours the commitments made to the study participants in the consent 458 documentation and ethical approvals, and is compliant with relevant legal and regulatory 459 requirements (e.g. relating to data protection and privacy). The Steering Committee will 460 have the right to review and comment on any draft manuscripts prior to publication. Data 461 will be made available in line with the policy and procedures described at: Authorizes Drug Combination for Treatment of COVID-19. 2020. 527

https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-528

fda-authorizes-drug-combination-treatment-covid-19 (accessed 21 Feb 2022). 529 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 3, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Data are mean (SD), n (%), or median (IQR). 33 children and no pregnant women were randomised. 2 post-partum women were randomised to baricitinib *Defined as requiring ongoing specialist care. †Defined as estimated glomerular filtration rate <30 mL/min/1.73 m² . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Data are n (%) or n/N (%), unless otherwise indicated. RR=rate ratio for the outcomes of 28-day mortality, hospital discharge and successful cessation of invasive mechanical ventilation, and risk ratio for other outcomes. CI=confidence interval.

Estimates of the RR and its 95% CI are adjusted for age in three categories (<70 years, 70-79 years, and 80 years or older). * Analyses exclude those on invasive mechanical ventilation at randomisation. † Analyses exclude those on any form of ventilation at randomisation. ‡ Analyses restricted to those on invasive mechanical ventilation at randomisation. § Analyses exclude those on haemodialysis or haemofiltration at randomisation.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101/2022.03.02.22271623 doi: medRxiv preprint ITT=intention to treat. Baricitinib unavailable and baricitinib unsuitable groups are not mutually exclusive. *Number recruited overall during the period that adult participants could be recruited into the baricitinib comparison.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Subgroup−specific rate ratio estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines through them correspond to 95% CIs. The days since onset and use of corticosteroids subgroups exclude patients with missing data, but these patients are included in the overall summary diamond. RR=age adjusted rate ratio.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. *** These trials did not assess baricitinib but assessed another JAK inhibitor. Restricting the meta−analysis to RECOVERY plus the 3 other baricitinib trials the RR would be 0.81 (95% CI 0.73−0.91).

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 3, 2022. ; https://doi.org/10.1101/2022.03.02.22271623 doi: medRxiv preprint

Features of 20 133 UK patients in 496 hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: 497 prospective observational cohort study

An inflammatory cytokine 499 signature predicts COVID-19 severity and survival

Ruxolitinib in treatment of severe coronavirus disease 530 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Efficacy and safety of baricitinib plus 533 standard of care for the treatment of critically ill hospitalised adults with COVID-19 on 534 invasive mechanical ventilation or extracorporeal membrane oxygenation: an 535 exploratory, randomised, placebo-controlled trial

Tofacitinib in Patients Hospitalized 537 with Covid-19 Pneumonia

Efficacy and safety of baricitinib for 539 the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, 540 double-blind, parallel-group, placebo-controlled phase 3 trial. The Lancet Respiratory 541

This manuscript was initially drafted by the PWH and MJL, further developed by the 417Writing Committee, and approved by all members of the Trial Steering Committee. PWH 418 and MJL vouch for the data and analyses, and for the fidelity of this report to the study 419